Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21168335 | 0.94 | MME (0.40) | F2PLGFKBP1AMMEMMEL1 | |
| SCHEMBL21168334 | 0.94 | MME (0.40) | F2PLGFKBP1AMMEMMEL1 | |
| SCHEMBL25476870 | 0.90 | F2 (0.32) | F2 | |
| SCHEMBL25476866 | 0.89 | VSIR (0.33) | F2FKBP1A | |
| SCHEMBL25476843 | 0.88 | ACE (0.32) | F2ACE | |
| SCHEMBL25476867 | 0.88 | VSIR (0.35) | F2 | |
| SCHEMBL21168491 | 0.87 | FKBP1A (0.41) | F2FKBP1AACE | |
| SCHEMBL25476845 | 0.87 | VSIR (0.31) | F2 | |
| SCHEMBL25476873 | 0.87 | DPP4 (0.39) | — | |
| SCHEMBL25476868 | 0.86 | OPRM1 (0.32) | F2ACEOPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | F2 4693/4885PLG 4364/4885FKBP1A 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.